Free Trial

Alnylam Pharmaceuticals (ALNY) Financials

Alnylam Pharmaceuticals logo
$285.56 -4.54 (-1.56%)
Closing price 05/28/2025 04:00 PM Eastern
Extended Trading
$285.55 -0.01 (0.00%)
As of 05/28/2025 04:24 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Annual Income Statements for Alnylam Pharmaceuticals

Annual Income Statements for Alnylam Pharmaceuticals

This table shows Alnylam Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015
Net Income / (Loss) Attributable to Common Shareholders
-278 -440 -1,131 -853 -858 -886 -761 -491 -410 -290
Consolidated Net Income / (Loss)
-278 -440 -1,131 -853 -858 -886 -761 -491 -410 -290
Net Income / (Loss) Continuing Operations
-278 -440 -1,131 -853 -858 -886 -761 -491 -410 -290
Total Pre-Tax Income
-377 -434 -1,127 -852 -856 -885 -761 -491 -410 -290
Total Operating Income
-177 -282 -785 -709 -828 -939 -815 -500 -425 -296
Total Gross Profit
1,925 1,518 869 704 415 195 73 90 47 41
Total Revenue
2,248 1,828 1,037 844 493 220 75 90 47 41
Operating Revenue
2,248 1,828 1,037 844 493 220 75 90 47 41
Total Cost of Revenue
323 310 169 140 78 25 1.80 0.00 0.00 0.00
Operating Cost of Revenue
323 310 169 140 78 25 1.80 0.00 - -
Total Operating Expenses
2,102 1,800 1,654 1,413 1,243 1,134 888 590 472 337
Selling, General & Admin Expense
976 796 771 621 588 479 382 199 89 61
Research & Development Expense
1,126 1,004 883 792 655 655 505 391 382 276
Total Other Income / (Expense), net
-200 -151 -342 -143 -27 54 54 9.21 14 5.94
Interest Expense
142 121 233 143 84 0.00 0.00 - - -
Interest & Investment Income
122 96 25 1.58 - 33 29 12 8.31 5.86
Other Income / (Expense), net
-181 -126 -134 -2.05 57 21 25 -3.02 6.17 0.08
Income Tax Expense
-99 6.73 4.16 0.68 2.68 0.86 0.82 0.00 0.00 -
Basic Earnings per Share
($2.18) ($3.52) ($9.30) ($7.20) ($7.46) ($8.11) ($7.57) ($5.42) ($4.79) ($3.45)
Weighted Average Basic Shares Outstanding
127.65M 124.91M 121.69M 118.45M 114.99M 109.26M 100.59M 90.55M 85.60M 83.99M
Diluted Earnings per Share
($2.18) ($3.52) ($9.30) ($7.20) ($7.46) ($8.11) ($7.57) ($5.42) ($4.79) ($3.45)
Weighted Average Diluted Shares Outstanding
127.65M 124.91M 121.69M 118.45M 114.99M 109.26M 100.59M 90.55M 85.60M 83.99M
Weighted Average Basic & Diluted Shares Outstanding
129.46M 125.95M 124.13M 120.21M 114.99M 109.26M 100.59M 90.55M 85.60M 83.99M

Quarterly Income Statements for Alnylam Pharmaceuticals

This table shows Alnylam Pharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Income / (Loss) Attributable to Common Shareholders
-57 -84 -112 -17 -66 -138 148 -276 -174 -207 -406
Consolidated Net Income / (Loss)
-57 -84 -112 -17 -66 -138 148 -276 -174 -207 -406
Net Income / (Loss) Continuing Operations
-57 -84 -112 -17 -66 -138 148 -276 -174 -207 -406
Total Pre-Tax Income
-42 -194 -109 -11 -64 -138 151 -274 -172 -207 -406
Total Operating Income
18 -105 -77 49 -43 -116 214 -230 -150 -189 -258
Total Gross Profit
523 490 415 591 428 354 666 233 264 284 223
Total Revenue
594 593 501 660 494 440 751 319 319 335 264
Operating Revenue
594 593 501 660 494 440 751 319 319 335 264
Total Cost of Revenue
71 103 86 69 66 86 84 85 55 51 41
Operating Cost of Revenue
71 103 86 69 66 86 84 85 55 51 41
Total Operating Expenses
505 596 492 543 472 470 452 463 414 472 481
Selling, General & Admin Expense
240 295 221 248 211 198 199 215 184 210 236
Research & Development Expense
265 300 271 294 261 272 253 249 231 262 245
Total Other Income / (Expense), net
-60 -89 -32 -60 -20 -21 -63 -44 -23 -18 -148
Interest Expense
39 39 34 33 35 31 31 30 29 30 118
Interest & Investment Income
29 31 32 29 30 30 25 21 19 14 7.82
Other Income / (Expense), net
-50 -81 -30 -56 -15 -20 -58 -35 -12 -2.57 -38
Income Tax Expense
16 -110 2.91 5.72 2.35 0.18 2.99 1.82 1.74 0.47 -0.02
Basic Earnings per Share
($0.44) ($0.66) ($0.87) ($0.13) ($0.52) ($1.09) $1.18 ($2.21) ($1.40) ($1.69) ($3.32)
Weighted Average Basic Shares Outstanding
129.68M 127.65M 128.59M 126.73M 126.14M 124.91M 125.22M 124.66M 124.11M 121.69M 122.17M
Diluted Earnings per Share
($0.44) ($0.66) ($0.87) ($0.13) ($0.52) ($1.06) $1.15 ($2.21) ($1.40) ($1.69) ($3.32)
Weighted Average Diluted Shares Outstanding
129.68M 127.65M 128.59M 126.73M 126.14M 124.91M 131.34M 124.66M 124.11M 121.69M 122.17M
Weighted Average Basic & Diluted Shares Outstanding
130.39M 129.46M 128.98M 128.38M 126.49M 125.95M 125.49M 125.00M 124.53M 124.13M 123.03M

Annual Cash Flow Statements for Alnylam Pharmaceuticals

This table details how cash moves in and out of Alnylam Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015
Net Change in Cash & Equivalents
154 -54 46 323 -51 127 -224 452 13 106
Net Cash From Operating Activities
-8.31 104 -541 -642 -615 -278 -563 -383 -308 -189
Net Cash From Continuing Operating Activities
-8.31 104 -541 -642 -615 -278 -563 -383 -308 -189
Net Income / (Loss) Continuing Operations
-278 -440 -1,131 -853 -858 -886 -761 -491 -410 -290
Consolidated Net Income / (Loss)
-278 -440 -1,131 -853 -858 -886 -761 -491 -410 -290
Depreciation Expense
57 54 44 48 35 17 15 12 15 19
Non-Cash Adjustments To Reconcile Net Income
402 345 445 227 170 164 170 95 72 47
Changes in Operating Assets and Liabilities, net
-189 145 101 -105 -1.44 390 14 1.48 15 35
Net Cash From Investing Activities
-117 -336 169 -273 -436 -418 273 -290 143 -321
Net Cash From Continuing Investing Activities
-117 -336 169 -273 -436 -418 273 -290 143 -321
Purchase of Property, Plant & Equipment
-34 -62 -72 -76 -70 -140 -127 -104 -65 -13
Purchase of Investments
-1,712 -1,882 -2,075 -1,698 -2,052 -2,076 -1,119 -903 -909 -1,035
Sale and/or Maturity of Investments
1,630 1,612 2,322 1,506 1,692 1,805 1,519 717 1,116 727
Other Investing Activities, net
-0.12 -4.44 -4.69 -4.20 -5.30 -7.00 0.00 0.00 - -
Net Cash From Financing Activities
294 172 426 1,247 995 823 65 1,125 178 616
Net Cash From Continuing Financing Activities
294 172 426 1,247 995 823 65 1,125 178 616
Repayment of Debt
0.00 0.00 -762 500 0.00 - 0.00 -120 - -
Issuance of Debt
0.00 0.00 1,016 0.00 200 0.00 0.00 - 150 -
Issuance of Common Equity
303 147 259 246 300 853 65 1,245 28 617
Other Financing Activities, net
-8.79 25 -88 501 495 -30 0.00 - -0.60 0.38
Effect of Exchange Rate Changes
-15 6.39 -7.43 -9.02 4.92 -0.08 - - - -
Cash Interest Paid
68 32 45 25 0.00 0.17 - 2.43 1.10 -
Cash Income Taxes Paid
14 6.02 2.65 - - - - 0.11 0.11 0.07

Quarterly Cash Flow Statements for Alnylam Pharmaceuticals

This table details how cash moves in and out of Alnylam Pharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Change in Cash & Equivalents
54 -134 131 286 -130 -220 375 -14 -194 -207 498
Net Cash From Operating Activities
-118 -95 44 124 -82 -30 359 -59 -166 -132 -115
Net Cash From Continuing Operating Activities
-118 -95 44 124 -82 -30 359 -59 -166 -132 -115
Net Income / (Loss) Continuing Operations
-57 -84 -112 -17 -66 -138 148 -276 -174 -207 -406
Consolidated Net Income / (Loss)
-57 -84 -112 -17 -66 -138 148 -276 -174 -207 -406
Depreciation Expense
14 14 14 15 14 13 13 13 14 14 11
Non-Cash Adjustments To Reconcile Net Income
93 127 78 120 77 69 108 101 67 61 237
Changes in Operating Assets and Liabilities, net
-168 -117 50 -3.84 -118 58 80 93 -86 31 33
Net Cash From Investing Activities
114 -53 -30 34 -68 -241 -11 -8.71 -76 -140 314
Net Cash From Continuing Investing Activities
114 -53 -30 34 -68 -241 -11 -8.71 -76 -140 314
Purchase of Property, Plant & Equipment
-8.97 -9.09 -4.19 -8.02 -13 -15 -17 -16 -14 -22 -17
Purchase of Investments
-450 -487 -450 -316 -460 -589 -421 -386 -485 -723 -223
Sale and/or Maturity of Investments
573 443 424 358 405 364 432 394 423 605 558
Net Cash From Financing Activities
44 31 103 131 29 39 33 53 46 63 297
Net Cash From Continuing Financing Activities
44 31 103 131 29 39 33 53 46 63 297
Issuance of Common Equity
49 36 108 133 26 31 25 49 42 57 153
Other Financing Activities, net
-5.28 -5.28 -5.28 -1.28 3.05 8.33 8.33 4.00 4.00 7.50 -111
Effect of Exchange Rate Changes
14 -17 15 -3.12 -9.94 11 -6.55 -0.13 2.18 1.62 2.02
Cash Interest Paid
67 12 16 8.16 31 5.44 9.55 3.22 14 1.30 15
Cash Income Taxes Paid
2.97 - - - - - - - - - -

Annual Balance Sheets for Alnylam Pharmaceuticals

This table presents Alnylam Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015
Total Assets
4,240 3,830 3,546 3,643 3,407 2,395 1,575 1,995 1,263 1,387
Total Current Assets
3,295 2,983 2,692 2,809 2,615 1,716 1,201 1,765 672 1,105
Cash & Equivalents
966 813 866 820 497 547 420 645 194 181
Short-Term Investments
1,728 1,627 1,326 1,616 1,378 989 664 1,045 433 900
Accounts Receivable
405 328 238 199 102 43 19 34 23 8.30
Inventories, net
79 89 129 86 75 56 24 - - -
Prepaid Expenses
117 126 133 88 63 80 74 40 22 17
Plant, Property, & Equipment, net
503 526 523 502 465 425 321 182 115 28
Total Noncurrent Assets
442 321 331 333 327 254 53 48 476 253
Long-Term Investments
69 49 49 41 41 15 45 44 475 252
Noncurrent Deferred & Refundable Income Taxes
117 10 - - - - - - - -
Other Noncurrent Operating Assets
256 262 281 292 287 239 8.62 4.17 1.56 1.47
Total Liabilities & Shareholders' Equity
4,240 3,830 3,546 3,643 3,407 2,395 1,575 1,995 1,263 1,387
Total Liabilities
4,173 4,051 3,705 3,055 2,391 956 273 228 343 122
Total Current Liabilities
1,186 968 768 696 585 353 179 144 132 62
Accounts Payable
88 56 98 73 52 50 60 28 54 17
Accrued Expenses
887 713 545 395 356 197 113 72 42 29
Current Deferred Revenue
55 103 42 149 127 78 7.07 44 35 17
Other Current Liabilities
155 97 82 78 50 28 0.00 - - -
Total Noncurrent Liabilities
2,987 3,083 2,937 2,359 1,614 604 93 84 211 60
Long-Term Debt
1,025 1,021 1,017 676 - 0.00 30 30 150 -
Noncurrent Deferred Revenue
0.00 188 194 152 225 318 58 50 58 58
Other Noncurrent Operating Liabilities
1,962 1,874 1,726 1,531 1,389 285 4.97 4.35 3.07 1.30
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
67 -221 -158 588 1,016 1,439 1,302 1,766 920 1,265
Total Preferred & Common Equity
67 -221 -158 588 1,016 1,439 1,302 1,766 920 1,265
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
67 -221 -158 588 1,016 1,439 1,302 1,766 920 1,265
Common Stock
7,389 6,812 6,456 6,060 5,645 5,202 4,176 3,949 2,610 2,507
Retained Earnings
-7,288 -7,010 -6,569 -5,438 -4,585 -3,727 -2,841 -2,148 -1,657 -1,247
Accumulated Other Comprehensive Income / (Loss)
-35 -23 -45 -33 -44 -37 -33 -34 -33 4.37

Quarterly Balance Sheets for Alnylam Pharmaceuticals

This table presents Alnylam Pharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q3 2024 Q2 2024 Q1 2024 Q3 2023 Q2 2023 Q1 2023 Q3 2022
Period end date 3/31/2025 9/30/2024 6/30/2024 3/31/2024 9/30/2023 6/30/2023 3/31/2023 9/30/2022
Total Assets
4,214 4,205 4,010 3,824 3,839 3,402 3,392 3,535
Total Current Assets
3,268 3,355 3,173 2,989 2,985 2,524 2,541 2,691
Cash & Equivalents
1,020 1,100 968 682 1,033 658 672 1,073
Short-Term Investments
1,613 1,680 1,656 1,689 1,373 1,400 1,398 1,192
Accounts Receivable
418 354 309 321 325 221 219 185
Inventories, net
66 76 84 94 96 100 132 115
Prepaid Expenses
152 145 155 202 158 145 119 126
Plant, Property, & Equipment, net
499 507 517 523 526 527 523 515
Total Noncurrent Assets
447 343 320 312 328 351 328 330
Long-Term Investments
69 69 49 49 49 49 49 49
Noncurrent Deferred & Refundable Income Taxes
107 - - - - - - -
Other Noncurrent Operating Assets
271 274 270 263 279 301 279 280
Total Liabilities & Shareholders' Equity
4,214 4,205 4,010 3,824 3,839 3,402 3,392 3,535
Total Liabilities
4,098 4,173 4,013 4,044 4,005 3,811 3,651 3,603
Total Current Liabilities
1,076 1,221 1,055 942 950 789 673 773
Accounts Payable
97 71 74 78 74 60 62 41
Accrued Expenses
704 946 809 699 713 599 509 511
Current Deferred Revenue
28 71 69 77 77 55 36 144
Other Current Liabilities
246 133 104 88 86 76 67 77
Total Noncurrent Liabilities
3,023 2,952 2,957 3,102 3,055 3,022 2,978 2,830
Long-Term Debt
1,026 1,024 1,023 1,022 1,020 1,019 1,018 1,016
Other Noncurrent Operating Liabilities
1,997 1,927 1,932 1,895 1,839 1,809 1,769 1,681
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
115 32 -3.07 -219 -166 -408 -259 -68
Total Preferred & Common Equity
115 32 -3.07 -219 -166 -408 -259 -68
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
115 32 -3.07 -219 -166 -408 -259 -68
Common Stock
7,498 7,261 7,124 6,883 6,738 6,648 6,523 6,338
Retained Earnings
-7,345 -7,204 -7,092 -7,076 -6,872 -7,019 -6,743 -6,362
Accumulated Other Comprehensive Income / (Loss)
-38 -25 -35 -27 -32 -37 -39 -44

Annual Metrics And Ratios for Alnylam Pharmaceuticals

This table displays calculated financial ratios and metrics derived from Alnylam Pharmaceuticals' official financial filings.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015
Growth Metrics
- - - - - - - - - -
Revenue Growth
22.97% 76.23% 22.88% 71.31% 124.28% 193.36% -16.69% 90.66% 14.75% -18.72%
EBITDA Growth
14.97% 59.56% -40.86% 10.86% 19.40% -11.57% -57.71% -21.80% -45.65% 29.23%
EBIT Growth
12.34% 55.63% -29.34% 7.83% 16.07% -16.30% -57.01% -20.24% -41.39% 26.60%
NOPAT Growth
37.31% 64.06% -10.78% 14.46% 11.81% -15.31% -62.91% -17.78% -43.44% 26.91%
Net Income Growth
36.82% 61.08% -32.64% 0.64% 3.14% -16.37% -55.13% -19.69% -41.38% 19.51%
EPS Growth
38.07% 62.15% -29.17% 3.49% 8.01% -7.13% -39.67% -13.15% -38.84% 28.87%
Operating Cash Flow Growth
-107.98% 119.24% 15.65% -4.35% -120.87% 50.51% -46.98% -24.40% -62.68% -14.19%
Free Cash Flow Firm Growth
-230.57% 128.50% -4,357.02% -42.16% 104.50% 51.88% -60.46% -32.94% -85.48% 51.25%
Invested Capital Growth
1.02% -22.09% -14.06% -71.36% -530.12% -155.32% 227.96% 297.26% 53.62% -68.11%
Revenue Q/Q Growth
7.33% 6.07% 7.96% 12.67% 22.91% 29.95% -18.40% 29.48% 26.58% -28.61%
EBITDA Q/Q Growth
-45.28% 2.89% -0.48% -3.27% 10.94% -7.04% -9.62% -6.99% -4.89% -19.40%
EBIT Q/Q Growth
-15.98% 11.77% 3.51% -2.93% 9.34% -7.26% -10.52% -6.64% -4.17% -18.75%
NOPAT Q/Q Growth
5.98% 20.38% 0.75% -0.05% 11.14% -9.02% -9.85% -6.81% -5.71% -18.78%
Net Income Q/Q Growth
16.28% 13.66% 4.31% -1.78% 3.66% -7.88% -10.00% -6.35% -5.73% -31.41%
EPS Q/Q Growth
15.50% 15.18% 4.81% -0.84% 4.36% -4.38% -8.76% -3.24% -5.51% -45.57%
Operating Cash Flow Q/Q Growth
-114.70% 5,179.07% 3.25% -4.39% 10.59% -19.55% -9.20% -6.90% -8.95% -9.51%
Free Cash Flow Firm Q/Q Growth
-337.48% 949.02% -3.45% -77.55% 111.17% -38.06% -3.61% -4.44% -12.41% -3.81%
Invested Capital Q/Q Growth
6.77% -5.43% -1.22% -2.84% -9.95% 12.81% -10.37% 4.91% 16.85% -27.09%
Profitability Metrics
- - - - - - - - - -
Gross Margin
85.62% 83.02% 83.73% 83.40% 84.16% 88.60% 97.59% 100.00% 100.00% 100.00%
EBITDA Margin
-13.38% -19.35% -84.32% -73.55% -141.35% -393.33% -1,034.19% -546.33% -855.16% -673.73%
Operating Margin
-7.87% -15.43% -75.68% -83.94% -168.09% -427.50% -1,087.56% -556.20% -900.33% -720.27%
EBIT Margin
-15.90% -22.31% -88.61% -84.18% -156.46% -418.07% -1,054.54% -559.56% -887.25% -720.08%
Profit (Net Income) Margin
-12.37% -24.08% -109.04% -101.01% -174.15% -403.24% -1,016.58% -545.95% -869.63% -705.83%
Tax Burden Percent
73.71% 101.55% 100.37% 100.08% 100.31% 100.10% 100.11% 100.00% 100.00% 100.00%
Interest Burden Percent
105.56% 106.29% 122.60% 119.90% 110.96% 96.36% 96.30% 97.57% 98.01% 98.02%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% 0.00% 0.00% 0.00% 0.00% -1,450.22% -430.59% -2,294.21% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% 0.00% 0.00% 0.00% -1,432.97% -416.95% -2,283.60% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 0.00% 0.00% 0.00% 1,385.55% 380.96% 2,257.67% 0.00% 0.00%
Return on Equity (ROE)
362.29% 232.40% -526.14% -106.31% -69.92% -64.66% -49.63% -36.54% -37.54% -26.36%
Cash Return on Invested Capital (CROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -537.12% -716.28% 0.00% 0.00%
Operating Return on Assets (OROA)
-8.86% -11.06% -25.57% -20.16% -26.58% -46.28% -44.26% -30.89% -31.59% -24.00%
Return on Assets (ROA)
-6.89% -11.94% -31.47% -24.19% -29.58% -44.64% -42.67% -30.14% -30.96% -23.52%
Return on Common Equity (ROCE)
362.29% 232.40% -526.14% -106.31% -69.92% -64.66% -49.63% -36.54% -37.54% -26.36%
Return on Equity Simple (ROE_SIMPLE)
-414.62% 199.53% 714.91% -144.99% -84.46% -61.59% -58.49% -27.79% -44.57% -22.94%
Net Operating Profit after Tax (NOPAT)
-124 -198 -550 -496 -580 -658 -570 -350 -297 -207
NOPAT Margin
-5.51% -10.80% -52.97% -58.75% -117.66% -299.25% -761.30% -389.34% -630.23% -504.19%
Net Nonoperating Expense Percent (NNEP)
-9.63% -18.03% -38.45% -20.24% -17.00% -17.25% -13.64% -10.60% -9.89% -7.18%
Return On Investment Capital (ROIC_SIMPLE)
-11.34% -24.69% -64.00% - - - - - - -
Cost of Revenue to Revenue
14.38% 16.98% 16.27% 16.60% 15.84% 11.40% 2.41% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue
43.39% 43.52% 74.29% 73.51% 119.39% 217.98% 510.44% 221.73% 189.47% 147.48%
R&D to Revenue
50.09% 54.94% 85.12% 93.83% 132.86% 298.12% 674.72% 434.46% 810.86% 672.79%
Operating Expenses to Revenue
93.48% 98.46% 159.40% 167.34% 252.25% 516.10% 1,185.16% 656.20% 1,000.33% 820.27%
Earnings before Interest and Taxes (EBIT)
-358 -408 -919 -711 -771 -919 -790 -503 -418 -296
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-301 -354 -875 -621 -697 -864 -775 -491 -403 -277
Valuation Ratios
- - - - - - - - - -
Price to Book Value (P/BV)
452.40 0.00 0.00 34.48 14.86 8.93 5.66 6.67 3.49 6.31
Price to Tangible Book Value (P/TBV)
452.40 0.00 0.00 34.48 14.86 8.93 5.66 6.67 3.49 6.31
Price to Revenue (P/Rev)
13.50 13.14 28.18 24.02 30.64 58.43 98.34 131.03 68.13 194.10
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.00 0.00 0.00 0.00 0.00 0.00 30.87 162.81 0.00 0.00
Enterprise Value to Revenue (EV/Rev)
12.73 12.34 27.00 21.89 26.75 51.37 83.66 112.08 47.95 161.68
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 216.53 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 208.74 0.00 2,075.70 856.53 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - - - -
Debt to Equity
15.27 -4.63 -6.43 1.15 0.00 0.00 0.02 0.02 0.16 0.00
Long-Term Debt to Equity
15.27 -4.63 -6.43 1.15 0.00 0.00 0.02 0.02 0.16 0.00
Financial Leverage
20.88 7.11 -7.04 -2.20 -1.33 -0.97 -0.91 -0.99 -1.05 -1.05
Leverage Ratio
-52.55 -19.47 16.72 4.39 2.36 1.45 1.16 1.21 1.21 1.12
Compound Leverage Factor
-55.47 -20.69 20.50 5.27 2.62 1.40 1.12 1.18 1.19 1.10
Debt to Total Capital
93.85% 127.58% 118.43% 53.46% 0.00% 0.00% 2.25% 1.67% 14.02% 0.00%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
93.85% 127.58% 118.43% 53.46% 0.00% 0.00% 2.25% 1.67% 14.02% 0.00%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
6.15% -27.58% -18.43% 46.54% 100.00% 100.00% 97.75% 98.33% 85.98% 100.00%
Debt to EBITDA
-3.41 -2.89 -1.16 -1.09 0.00 0.00 -0.04 -0.06 -0.37 0.00
Net Debt to EBITDA
5.78 4.15 1.40 2.90 0.00 0.00 1.42 3.47 2.36 0.00
Long-Term Debt to EBITDA
-3.41 -2.89 -1.16 -1.09 0.00 0.00 -0.04 -0.06 -0.37 0.00
Debt to NOPAT
-8.28 -5.17 -1.85 -1.36 0.00 0.00 -0.05 -0.09 -0.50 0.00
Net Debt to NOPAT
14.04 7.43 2.23 3.63 0.00 0.00 1.93 4.87 3.20 0.00
Long-Term Debt to NOPAT
-8.28 -5.17 -1.85 -1.36 0.00 0.00 -0.05 -0.09 -0.50 0.00
Altman Z-Score
2.81 1.75 2.23 2.18 2.02 5.39 12.84 29.64 3.25 38.27
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - -
Current Ratio
2.78 3.08 3.51 4.04 4.47 4.87 6.69 12.23 5.10 17.80
Quick Ratio
2.61 2.86 3.16 3.79 3.38 4.48 6.14 11.96 4.94 17.53
Cash Flow Metrics
- - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-141 108 -379 8.90 15 -342 -711 -443 -333 -180
Operating Cash Flow to CapEx
-24.25% 167.42% -751.15% -840.22% -874.01% -198.66% -443.40% -367.33% -476.63% -1,460.54%
Free Cash Flow to Firm to Interest Expense
-0.99 0.89 -1.63 0.06 0.18 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense
-0.06 0.86 -2.33 -4.49 -7.28 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense
-0.30 0.35 -2.64 -5.02 -8.11 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios
- - - - - - - - - -
Asset Turnover
0.56 0.50 0.29 0.24 0.17 0.11 0.04 0.06 0.04 0.03
Accounts Receivable Turnover
6.13 6.46 4.75 5.61 6.78 7.12 2.84 3.14 2.98 1.70
Inventory Turnover
3.86 2.85 1.57 1.73 1.19 0.62 0.00 0.00 0.00 0.00
Fixed Asset Turnover
4.37 3.48 2.02 1.75 1.11 0.59 0.30 0.61 0.66 1.66
Accounts Payable Turnover
4.49 4.04 1.97 2.24 1.53 0.46 0.04 0.00 0.00 0.00
Days Sales Outstanding (DSO)
59.51 56.47 76.79 65.06 53.85 51.30 128.55 116.38 122.41 214.20
Days Inventory Outstanding (DIO)
94.62 128.23 232.78 210.40 307.59 585.58 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)
81.23 90.32 185.42 163.29 238.14 798.04 8,918.70 0.00 0.00 0.00
Cash Conversion Cycle (CCC)
72.90 94.39 124.15 112.17 123.29 -161.16 -8,790.15 116.38 122.41 214.20
Capital & Investment Metrics
- - - - - - - - - -
Invested Capital
-1,671 -1,689 -1,383 -1,213 -708 -112 203 62 -31 -68
Invested Capital Turnover
-1.34 -1.19 -0.80 -0.88 -1.20 4.85 0.57 5.89 -0.95 -0.76
Increase / (Decrease) in Invested Capital
17 -306 -171 -505 -595 -315 141 93 36 -27
Enterprise Value (EV)
28,612 22,553 28,013 18,481 13,185 11,289 6,267 10,077 2,261 6,645
Market Capitalization
30,350 24,021 29,238 20,282 15,100 12,840 7,366 11,781 3,213 7,977
Book Value per Share
$0.52 ($1.76) ($1.29) $4.92 $8.75 $12.90 $12.89 $19.05 $10.72 $14.93
Tangible Book Value per Share
$0.52 ($1.76) ($1.29) $4.92 $8.75 $12.90 $12.89 $19.05 $10.72 $14.93
Total Capital
1,092 800 859 1,264 1,016 1,439 1,332 1,796 1,070 1,265
Total Debt
1,025 1,021 1,017 676 0.00 0.00 30 30 150 0.00
Total Long-Term Debt
1,025 1,021 1,017 676 0.00 0.00 30 30 150 0.00
Net Debt
-1,738 -1,468 -1,225 -1,801 -1,915 -1,551 -1,099 -1,705 -952 -1,332
Capital Expenditures (CapEx)
34 62 72 76 70 140 127 104 65 13
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-585 -424 -268 -323 155 -173 -63 -70 -87 -37
Debt-free Net Working Capital (DFNWC)
2,109 2,015 1,924 2,113 2,030 1,363 1,021 1,620 540 1,043
Net Working Capital (NWC)
2,109 2,015 1,924 2,113 2,030 1,363 1,021 1,620 540 1,043
Net Nonoperating Expense (NNE)
154 243 582 357 278 229 191 141 113 83
Net Nonoperating Obligations (NNO)
-1,738 -1,468 -1,225 -1,801 -1,724 -1,551 -1,099 -1,705 -952 -1,332
Total Depreciation and Amortization (D&A)
57 54 44 90 74 54 15 12 15 19
Debt-free, Cash-free Net Working Capital to Revenue
-26.04% -23.22% -25.84% -38.22% 31.47% -78.68% -84.04% -78.00% -183.68% -90.62%
Debt-free Net Working Capital to Revenue
93.81% 110.21% 185.49% 250.25% 411.79% 620.37% 1,363.28% 1,802.31% 1,145.44% 2,538.60%
Net Working Capital to Revenue
93.81% 110.21% 185.49% 250.25% 411.79% 620.37% 1,363.28% 1,802.31% 1,145.44% 2,538.60%
Earnings Adjustments
- - - - - - - - - -
Adjusted Basic Earnings per Share
($2.18) ($3.52) ($9.30) ($7.20) ($7.46) ($8.11) ($7.57) ($5.42) ($4.79) ($3.45)
Adjusted Weighted Average Basic Shares Outstanding
127.65M 124.91M 121.69M 118.45M 117.00M 112.58M 106.26M 99.87M 86.01M 85.14M
Adjusted Diluted Earnings per Share
($2.18) ($3.52) ($9.30) ($7.20) ($7.46) ($8.11) ($7.57) ($5.42) ($4.79) ($3.45)
Adjusted Weighted Average Diluted Shares Outstanding
127.65M 124.91M 121.69M 118.45M 117.00M 112.58M 106.26M 99.87M 86.01M 85.14M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 ($7.46) ($8.11) ($7.57) ($5.42) ($4.79) ($3.45)
Adjusted Weighted Average Basic & Diluted Shares Outstanding
129.46M 125.95M 124.13M 120.21M 114.99M 109.26M 100.59M 90.55M 85.60M 83.99M
Normalized Net Operating Profit after Tax (NOPAT)
-124 -198 -550 -496 -580 -658 -570 -350 -297 -207
Normalized NOPAT Margin
-5.51% -10.80% -52.97% -58.75% -117.66% -299.25% -761.30% -389.34% -630.23% -504.19%
Pre Tax Income Margin
-16.79% -23.71% -108.63% -100.93% -173.60% -402.85% -1,015.48% -545.95% -869.63% -705.83%
Debt Service Ratios
- - - - - - - - - -
EBIT to Interest Expense
-2.52 -3.36 -3.95 -4.97 -9.13 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense
-0.87 -1.63 -2.36 -3.47 -6.86 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense
-2.76 -3.88 -4.26 -5.50 -9.96 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense
-1.11 -2.14 -2.67 -4.00 -7.70 0.00 0.00 0.00 0.00 0.00
Payout Ratios
- - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Alnylam Pharmaceuticals

This table displays calculated financial ratios and metrics derived from Alnylam Pharmaceuticals' official financial filings.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Growth Metrics
- - - - - - - - - - -
Revenue Growth
20.20% 34.90% -33.26% 107.00% 54.82% 31.25% 183.96% 41.78% 49.72% 29.59% 40.86%
EBITDA Growth
61.27% -39.40% -144.17% 107.28% 76.11% 30.30% 165.26% -13.14% 23.70% 12.94% -95.71%
EBIT Growth
45.46% -36.01% -168.14% 97.33% 64.22% 28.47% 152.76% -13.37% 18.15% 14.88% -80.59%
NOPAT Growth
141.62% 9.66% -125.68% 121.15% 71.01% 38.28% 216.05% -19.90% -2.10% 3.06% -42.03%
Net Income Growth
12.82% 39.24% -175.51% 93.88% 62.13% 33.55% 136.40% 0.50% 27.56% 19.72% -98.48%
EPS Growth
15.38% 37.74% -175.65% 94.12% 62.86% 37.28% 134.64% 3.49% 30.00% 21.76% -93.02%
Operating Cash Flow Growth
-45.14% -217.71% -87.84% 310.49% 51.03% 77.42% 411.76% 51.97% 2.76% 12.10% 13.99%
Free Cash Flow Firm Growth
-120.21% -140.55% -69.15% 561.59% 319.44% 482.15% 6,551.30% -94.39% -88.45% -89.56% -98.36%
Invested Capital Growth
3.61% 1.02% -11.93% -10.58% -18.86% -22.09% -17.22% -14.54% -13.21% -14.06% -15.89%
Revenue Q/Q Growth
0.17% 18.42% -24.08% 33.48% 12.42% -41.41% 135.46% -0.17% -4.70% 26.76% 17.56%
EBITDA Q/Q Growth
89.98% -116.43% -551.08% 154.17% 71.19% -168.58% 174.33% -77.82% 18.23% 35.79% -28.88%
EBIT Q/Q Growth
83.00% -74.76% -1,400.96% 87.77% 57.60% -187.55% 158.89% -63.67% 15.23% 35.43% -26.56%
NOPAT Q/Q Growth
117.19% -36.74% -258.20% 211.92% 62.69% -138.87% 230.30% -53.42% 20.57% 26.91% -34.62%
Net Income Q/Q Growth
31.38% 24.92% -560.61% 74.39% 52.18% -193.31% 153.53% -58.54% 16.09% 48.88% -46.33%
EPS Q/Q Growth
33.33% 24.14% -569.23% 75.00% 50.94% -192.17% 152.04% -57.86% 17.16% 49.10% -44.98%
Operating Cash Flow Q/Q Growth
-24.99% -316.58% -64.80% 252.31% -173.59% -108.29% 709.32% 64.57% -26.14% -14.48% 6.14%
Free Cash Flow Firm Q/Q Growth
49.66% -166.20% -28.61% -15.07% 1.03% -49.64% 1,431.15% -46.16% 40.22% 475.37% -98.71%
Invested Capital Q/Q Growth
6.68% 6.77% -8.37% -2.24% 4.17% -5.43% -7.05% -9.90% 1.57% -1.22% -4.60%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
88.04% 82.67% 82.85% 89.59% 86.65% 80.47% 88.77% 73.22% 82.82% 84.70% 84.44%
EBITDA Margin
-2.90% -28.97% -15.85% 2.67% -6.57% -28.03% 23.95% -75.86% -42.59% -52.79% -104.21%
Operating Margin
3.04% -17.73% -15.35% 7.37% -8.79% -26.47% 28.50% -72.10% -46.92% -56.30% -97.63%
EBIT Margin
-5.32% -31.36% -21.25% -1.07% -11.73% -31.10% 20.81% -83.21% -50.76% -57.06% -112.03%
Profit (Net Income) Margin
-9.67% -14.12% -22.27% -2.56% -13.34% -31.35% 19.69% -86.59% -54.53% -61.93% -153.58%
Tax Burden Percent
138.18% 43.19% 102.68% 151.24% 103.69% 100.13% 98.02% 100.66% 101.01% 100.23% 99.99%
Interest Burden Percent
131.54% 104.28% 102.10% 157.48% 109.67% 100.68% 96.50% 103.38% 106.36% 108.28% 137.10%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 1.98% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)
519.47% 362.29% 497.73% 35.48% 138.80% 232.40% 436.71% 916.48% -1,500.66% -526.14% -343.51%
Cash Return on Invested Capital (CROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)
-3.11% -17.47% -11.07% -0.68% -6.51% -15.42% 9.73% -30.59% -17.01% -16.47% -30.72%
Return on Assets (ROA)
-5.65% -7.87% -11.60% -1.62% -7.41% -15.54% 9.20% -31.83% -18.27% -17.87% -42.12%
Return on Common Equity (ROCE)
519.47% 362.29% 497.73% 35.48% 138.80% 232.40% 436.71% 916.48% -1,500.66% -526.14% -343.51%
Return on Equity Simple (ROE_SIMPLE)
-233.64% 0.00% -1,026.96% 2,378.25% 151.44% 0.00% 307.40% 260.59% 410.78% 0.00% 1,747.72%
Net Operating Profit after Tax (NOPAT)
13 -74 -54 34 -30 -81 210 -161 -105 -132 -181
NOPAT Margin
2.13% -12.41% -10.75% 5.16% -6.15% -18.53% 27.93% -50.47% -32.84% -39.41% -68.34%
Net Nonoperating Expense Percent (NNEP)
-4.56% -0.63% -3.54% -3.72% -2.84% -4.19% -4.53% -8.96% -5.12% -4.99% -13.93%
Return On Investment Capital (ROIC_SIMPLE)
1.11% -6.74% - - - -10.18% - - - -15.38% -
Cost of Revenue to Revenue
11.96% 17.33% 17.15% 10.41% 13.35% 19.53% 11.23% 26.78% 17.18% 15.30% 15.56%
SG&A Expenses to Revenue
40.38% 49.79% 44.12% 37.65% 42.64% 45.06% 26.54% 67.35% 57.52% 62.78% 89.24%
R&D to Revenue
44.62% 50.60% 54.09% 44.58% 52.80% 61.89% 33.73% 77.97% 72.21% 78.21% 92.84%
Operating Expenses to Revenue
85.00% 100.39% 98.20% 82.22% 95.44% 106.95% 60.27% 145.32% 129.73% 141.00% 182.07%
Earnings before Interest and Taxes (EBIT)
-32 -186 -106 -7.09 -58 -137 156 -265 -162 -191 -296
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-17 -172 -79 18 -32 -123 180 -242 -136 -177 -275
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
302.82 452.40 1,091.32 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Tangible Book Value (P/TBV)
302.82 452.40 1,091.32 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)
14.89 13.50 16.86 13.11 9.36 13.14 12.84 19.11 21.75 28.18 25.00
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)
14.17 12.73 15.98 12.41 8.66 12.34 12.01 18.24 20.78 27.00 23.65
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 558.63 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 404.82 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 592.05 78.13 91.77 216.53 10,492.53 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 563.66 126.41 129.78 208.74 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
8.88 15.27 31.64 -333.45 -4.66 -4.63 -6.15 -2.50 -3.93 -6.43 -15.02
Long-Term Debt to Equity
8.88 15.27 31.64 -333.45 -4.66 -4.63 -6.15 -2.50 -3.93 -6.43 -15.02
Financial Leverage
29.61 20.88 24.43 6.66 5.23 7.11 11.71 11.07 -19.07 -7.04 -4.70
Leverage Ratio
-77.41 -52.55 -60.25 -18.03 -15.08 -19.47 -31.58 -29.01 48.09 16.72 10.18
Compound Leverage Factor
-101.83 -54.80 -61.51 -28.39 -16.54 -19.60 -30.48 -29.99 51.15 18.11 13.96
Debt to Total Capital
89.88% 93.85% 96.94% 100.30% 127.33% 127.58% 119.42% 166.83% 134.17% 118.43% 107.13%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
89.88% 93.85% 96.94% 100.30% 127.33% 127.58% 119.42% 166.83% 134.17% 118.43% 107.13%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
10.12% 6.15% 3.06% -0.30% -27.33% -27.58% -19.42% -66.83% -34.17% -18.43% -7.13%
Debt to EBITDA
-3.75 -3.41 -4.94 19.64 -4.93 -2.89 -2.80 -1.24 -1.29 -1.16 -1.17
Net Debt to EBITDA
6.12 5.78 8.81 -31.72 6.75 4.15 3.94 1.33 1.39 1.40 1.49
Long-Term Debt to EBITDA
-3.75 -3.41 -4.94 19.64 -4.93 -2.89 -2.80 -1.24 -1.29 -1.16 -1.17
Debt to NOPAT
-12.70 -8.28 -7.77 14.23 -8.30 -5.17 -4.11 -1.76 -1.85 -1.85 -1.83
Net Debt to NOPAT
20.74 14.04 13.86 -22.98 11.37 7.43 5.79 1.88 2.00 2.23 2.35
Long-Term Debt to NOPAT
-12.70 -8.28 -7.77 14.23 -8.30 -5.17 -4.11 -1.76 -1.85 -1.85 -1.83
Altman Z-Score
3.83 2.94 3.70 3.33 1.31 1.99 2.03 1.55 2.14 2.91 2.13
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
3.04 2.78 2.75 3.01 3.17 3.08 3.14 3.20 3.77 3.51 3.48
Quick Ratio
2.84 2.61 2.57 2.78 2.86 2.86 2.88 2.89 3.40 3.16 3.17
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-46 -91 137 192 226 224 445 29 54 38 6.69
Operating Cash Flow to CapEx
-1,319.00% -1,040.93% 1,042.63% 1,548.49% -628.34% -194.62% 2,102.81% -370.54% -1,198.44% -610.02% -698.27%
Free Cash Flow to Firm to Interest Expense
-1.18 -2.33 3.99 5.78 6.42 7.15 14.40 0.97 1.86 1.29 0.06
Operating Cash Flow to Interest Expense
-3.06 -2.43 1.27 3.73 -2.31 -0.95 11.63 -1.96 -5.75 -4.41 -0.98
Operating Cash Flow Less CapEx to Interest Expense
-3.29 -2.66 1.15 3.49 -2.68 -1.44 11.08 -2.49 -6.23 -5.14 -1.12
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.58 0.56 0.52 0.63 0.56 0.50 0.47 0.37 0.34 0.29 0.27
Accounts Receivable Turnover
6.35 6.13 6.17 8.84 7.41 6.46 6.76 6.82 6.08 4.75 5.90
Inventory Turnover
4.12 3.86 3.57 3.31 2.85 2.85 2.61 2.46 1.79 1.57 1.45
Fixed Asset Turnover
4.59 4.37 4.06 4.49 3.83 3.48 3.31 2.39 2.23 2.02 1.92
Accounts Payable Turnover
3.74 4.49 4.24 4.56 4.58 4.04 4.82 4.15 3.21 1.97 3.85
Days Sales Outstanding (DSO)
57.47 59.51 59.18 41.27 49.27 56.47 54.00 53.52 60.01 76.79 61.83
Days Inventory Outstanding (DIO)
88.67 94.62 102.30 110.43 128.21 128.23 139.79 148.61 204.18 232.78 250.90
Days Payable Outstanding (DPO)
97.55 81.23 86.15 80.06 79.69 90.32 75.70 88.00 113.69 185.42 94.79
Cash Conversion Cycle (CCC)
48.59 72.90 75.33 71.63 97.79 94.39 118.08 114.14 150.49 124.15 217.94
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
-1,560 -1,671 -1,793 -1,654 -1,618 -1,689 -1,602 -1,496 -1,361 -1,383 -1,366
Invested Capital Turnover
-1.48 -1.34 -1.23 -1.49 -1.34 -1.19 -1.16 -0.88 -0.89 -0.80 -0.76
Increase / (Decrease) in Invested Capital
58 17 -191 -158 -257 -306 -235 -190 -159 -171 -187
Enterprise Value (EV)
33,281 28,612 33,483 29,086 17,356 22,553 20,702 22,564 23,764 28,013 22,726
Market Capitalization
34,956 30,350 35,308 30,738 18,755 24,021 22,138 23,652 24,866 29,238 24,025
Book Value per Share
$0.89 $0.52 $0.25 ($0.02) ($1.74) ($1.76) ($1.33) ($3.28) ($2.09) ($1.29) ($0.56)
Tangible Book Value per Share
$0.89 $0.52 $0.25 ($0.02) ($1.74) ($1.76) ($1.33) ($3.28) ($2.09) ($1.29) ($0.56)
Total Capital
1,141 1,092 1,056 1,020 802 800 854 611 759 859 948
Total Debt
1,026 1,025 1,024 1,023 1,022 1,021 1,020 1,019 1,018 1,017 1,016
Total Long-Term Debt
1,026 1,025 1,024 1,023 1,022 1,021 1,020 1,019 1,018 1,017 1,016
Net Debt
-1,675 -1,738 -1,825 -1,651 -1,399 -1,468 -1,436 -1,088 -1,102 -1,225 -1,299
Capital Expenditures (CapEx)
8.97 9.09 4.19 8.02 13 15 17 16 14 22 17
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-440 -585 -645 -507 -324 -424 -371 -322 -203 -268 -347
Debt-free Net Working Capital (DFNWC)
2,193 2,109 2,135 2,118 2,047 2,015 2,036 1,735 1,868 1,924 1,918
Net Working Capital (NWC)
2,193 2,109 2,135 2,118 2,047 2,015 2,036 1,735 1,868 1,924 1,918
Net Nonoperating Expense (NNE)
70 10 58 51 36 56 62 115 69 75 225
Net Nonoperating Obligations (NNO)
-1,675 -1,738 -1,825 -1,651 -1,399 -1,468 -1,436 -1,088 -1,102 -1,225 -1,299
Total Depreciation and Amortization (D&A)
14 14 27 25 25 13 24 23 26 14 21
Debt-free, Cash-free Net Working Capital to Revenue
-18.72% -26.04% -30.81% -21.63% -16.19% -23.22% -21.50% -26.03% -17.76% -25.84% -36.14%
Debt-free Net Working Capital to Revenue
93.38% 93.81% 101.91% 90.33% 102.17% 110.21% 118.10% 140.25% 163.33% 185.49% 199.61%
Net Working Capital to Revenue
93.38% 93.81% 101.91% 90.33% 102.17% 110.21% 118.10% 140.25% 163.33% 185.49% 199.61%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
($0.44) ($0.66) ($0.87) ($0.13) ($0.52) ($1.09) $1.18 ($2.21) ($1.40) ($1.69) ($3.32)
Adjusted Weighted Average Basic Shares Outstanding
129.68M 127.65M 128.59M 126.73M 126.14M 124.91M 125.22M 124.66M 124.11M 121.69M 122.17M
Adjusted Diluted Earnings per Share
($0.44) ($0.66) ($0.87) ($0.13) ($0.52) ($1.06) $1.15 ($2.21) ($1.40) ($1.69) ($3.32)
Adjusted Weighted Average Diluted Shares Outstanding
129.68M 127.65M 128.59M 126.73M 126.14M 124.91M 131.34M 124.66M 124.11M 121.69M 122.17M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
130.39M 129.46M 128.98M 128.38M 126.49M 125.95M 125.49M 125.00M 124.53M 124.13M 123.03M
Normalized Net Operating Profit after Tax (NOPAT)
13 -74 -54 34 -30 -81 210 -161 -105 -132 -181
Normalized NOPAT Margin
2.13% -12.41% -10.75% 5.16% -6.15% -18.53% 27.93% -50.47% -32.84% -39.41% -68.34%
Pre Tax Income Margin
-7.00% -32.70% -21.69% -1.69% -12.86% -31.31% 20.08% -86.03% -53.98% -61.79% -153.59%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
-0.82 -4.77 -3.10 -0.21 -1.64 -4.36 5.06 -8.83 -5.60 -6.39 -2.52
NOPAT to Interest Expense
0.33 -1.89 -1.57 1.02 -0.86 -2.60 6.79 -5.36 -3.62 -4.41 -1.54
EBIT Less CapEx to Interest Expense
-1.05 -5.01 -3.22 -0.45 -2.01 -4.85 4.50 -9.36 -6.08 -7.11 -2.66
NOPAT Less CapEx to Interest Expense
0.10 -2.12 -1.69 0.78 -1.23 -3.09 6.23 -5.89 -4.10 -5.14 -1.68
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Frequently Asked Questions About Alnylam Pharmaceuticals' Financials

When does Alnylam Pharmaceuticals's financial year end?

According to the most recent income statement we have on file, Alnylam Pharmaceuticals' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Alnylam Pharmaceuticals' net income changed over the last 9 years?

Alnylam Pharmaceuticals' net income appears to be on an upward trend, with a most recent value of -$278.16 million in 2024, falling from -$290.07 million in 2015. The previous period was -$440.24 million in 2023. See where experts think Alnylam Pharmaceuticals is headed by visiting Alnylam Pharmaceuticals' forecast page.

What is Alnylam Pharmaceuticals's operating income?
Alnylam Pharmaceuticals's total operating income in 2024 was -$176.89 million, based on the following breakdown:
  • Total Gross Profit: $1.92 billion
  • Total Operating Expenses: $2.10 billion
How has Alnylam Pharmaceuticals revenue changed over the last 9 years?

Over the last 9 years, Alnylam Pharmaceuticals' total revenue changed from $41.10 million in 2015 to $2.25 billion in 2024, a change of 5,370.6%.

How much debt does Alnylam Pharmaceuticals have?

Alnylam Pharmaceuticals' total liabilities were at $4.17 billion at the end of 2024, a 3.0% increase from 2023, and a 3,326.1% increase since 2015.

How much cash does Alnylam Pharmaceuticals have?

In the past 9 years, Alnylam Pharmaceuticals' cash and equivalents has ranged from $180.90 million in 2015 to $966.43 million in 2024, and is currently $966.43 million as of their latest financial filing in 2024.

How has Alnylam Pharmaceuticals' book value per share changed over the last 9 years?

Over the last 9 years, Alnylam Pharmaceuticals' book value per share changed from 14.93 in 2015 to 0.52 in 2024, a change of -96.5%.



This page (NASDAQ:ALNY) was last updated on 5/29/2025 by MarketBeat.com Staff
From Our Partners